A review of methods for futility stopping based on conditional power

Statistics in Medicine

Volumn 24, Issue 18, 2005, Pages 2747-2764

  Lachin, John M ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Brownian motion; Conditional power; Futility; Interim analysis; Stochastic curtailing

Indexed keywords

ANALYTIC METHOD; ANALYTICAL ERROR; CALCULATION; MATHEMATICAL COMPUTING; PROBABILITY; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STATISTICS;

BIOMETRY; CLINICAL TRIALS; HUMANS; MODELS, STATISTICAL; PROBABILITY; STOCHASTIC PROCESSES;

EID: 25444474448     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.2151     Document Type: Review

References (34)

1. Halperin M, Lan KKG, Ware JH, Johnson NJ, DeMets DL. An aid to data monitoring in long-term clinical trials. Controlled Clinical Trials 1982; 3:311-323.
2. Lan KKG, Simon R, Halperin M. Stochastically curtailed tests in long-term clinical trials. Communications in Statistics C 1982; 1:207 219.
3. Davis BR, Hardy RJ. Upper bounds for type I and type II error rates in conditional power computations. Communications in Statistics - Theory and Methods 1990; 19:3571-3584.
4. Davis BR, Hardy RJ. Repeated confidence intervals and prediction intervals using stochastic curtailing. Communications in Statistics - Theory and Methods 1992; 21:351-368.
5. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663.
6. Lan KKG, Wittes J. The B-value: a tool for data monitoring. Biometrics 1988; 44:579-585.
7. Lan KKG, Zucker DM. Sequential monitoring of clinical trials: the role of information and Brownian motion. Statistics in Medicine 1993; 12:753-765.
8. Lan KKG, Reboussin DM, DeMets DL. Information and information fractions for design and sequential monitoring of clinical trials. Communications in Statistics - Theory and Methods 1994; 23:403-420.
9. Wu MC, Lan KKG. Sequential monitoring for comparison of changes in a response variable in clinical trials. Biometrics 1992; 48:765-779.
10. Tsiatis AA. Repeated significance testing for a general class of statistics used in censored survival analysis. Journal of the American Statistical Association 1982; 77:855-861.
11. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Controlled Clinical Trials 1981; 2:93-113.
12. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for non-uniform patient entry, losses to follow-up, non-compliance and stratification. Biometrics 1986; 42:507-519.
13. Lachin JM. Biostatistical Methods: The Assessment of Relative Risks. Wiley: New York, 2000.
14. Reboussin DM, DeMets DL, Kim K, Lan KKG. Computations for group sequential boundaries using the LanDeMets spending function method. Controlled Clinical Trials 2000; 21:190-207.
15. Strömberg U, Losic N, Lanke J. Incorporation of a stopping criterion for futility into the design of a clinical trial with one interim analysis. Communications in Statistics - Theory and Methods 1997; 26:1011-1030.
16. Armitage P, McPherson CK, Rowe BC. Repeated significance tests on accumulating data. Journal of the Royal Statistical Society, Series A 1969; 132:235-244.
17. Snapinn SM. Monitoring clinical trials with a conditional probability stopping rule. Statistics in Medicine 1992; 11:659-672.
18. Pepe MS, Anderson GL. Two-stage experimental designs: early stopping with a negative result. Applied Statistics 1992; 41:181-190.
19. Ware JH, Muller JE, Braunwald E. The futility index. American Journal of Medicine 1985; 78:635-643.
20. Lan KKG, Trost DC. Estimation of parameters and sample size re-estimation. Proceedings of the American Statistical Association Biopharmaceutical Section 1997; 48-51.
21. Ellenberg SS, Eisenberger MA. An efficient design for Phase III studies of combination chemotherapies. Cancer Treatment Reports 1985; 69:1147-1152.
22. Wieand S, Schroeder G, O'Fallon JR. Stopping when the experimental regimen does not appear to help. Statistics in Medicine 1994; 13:1453-1458.
23. Lin DY, Yao Q, Ying Z. A general theory on stochastic curtailment for censored survival data. Journal of the American Statistical Association 1999; 94:510-521.
24. Whitehead J, Matsushita T. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment. Statistics in Medicine 2003; 22:677-687.
25. Friedlin B, Korn EL. A comment on futility monitoring. Controlled Clinical Trials 2002; 23:355-366.
26. Pampallona S, Tsiatis AA. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. Journal of Statistical Planning and Inference 1994; 42:19-35.
27. 0 embedded in sequential tests. Statistics in Medicine 1997; 16:465-477.
28. 0 based on conditional power: approximations and comparisons. Biometrics 1997; 53:794-806.
29. DeMets DL, Ware JH. Asymmetric group sequential boundaries for monitoring clinical trials. Biometrika 1982; 69:661-663.
30. Wang SK, Tsiatis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 1987; 43:193-199.
31. Emerson SS, Fleming TR. Symmetric group sequential test designs. Biometrics 1989; 45:905-923.
32. Whitehead J. The Design and Analysis of Sequential Clinical Trials (2nd edn). Wiley: Chichester, 1997.
33. Kittleson JM, Emerson SS. A unifying family of group sequential test designs. Biometrics 1999; 55:874-882.
34. Pampallona S, Tsiatis AA, Kim KM. Interim monitoring of group sequential trials using spending functions for the type I and type II error probabilities. Drug Information Journal 2001; 35:1113-1121.